INTERNATIONAL JOURNAL OF DATA SCIENCE AND MACHINE LEARNING

academic publishers

International journal of biological sciences (ISSN: 2693-3608)

Volume 04, Issue 01, 2024, pages 22-25
Published Date: - 01-10-2024

OPTIMIZING REPAGLINIDE DELIVERY: FORMULATION AND EVALUATION OF BIPHASIC MINI TABLETS

Heena Khan
Department Of Pharmaceutics, Shadan Women's College Of Pharmacy, Khairtabad, India

Abstract

The optimization of repaglinide delivery is crucial for achieving effective glycemic control in patients with diabetes. This study focuses on the formulation and evaluation of biphasic mini tablets designed to enhance the controlled release of repaglinide. The objective was to develop a formulation that ensures a consistent therapeutic effect through a biphasic release mechanism, combining both immediate and extended release profiles. Repaglinide biphasic mini tablets were formulated using a combination of hydrophilic and hydrophobic polymers to achieve the desired drug release characteristics. The immediate release phase was designed to provide rapid onset of action, while the extended release phase aimed to maintain therapeutic drug levels over an extended period. Various formulation parameters, including polymer types, ratios, and tablet compression forces, were optimized through preliminary studies.

The mini tablets were evaluated for critical parameters including drug content uniformity, release kinetics, tablet hardness, and stability. In vitro dissolution studies were conducted to assess the release profiles and confirm the biphasic release pattern. The mini tablets demonstrated effective control over the release of repaglinide, with a significant improvement in the duration of therapeutic activity compared to conventional formulations. The results indicate that the biphasic mini tablets provide a promising approach for optimizing repaglinide delivery, offering both immediate and sustained drug release. This formulation strategy holds potential for improving glycemic control and patient adherence by providing a more consistent and prolonged therapeutic effect. Further clinical studies are warranted to confirm the efficacy and safety of this innovative delivery system in diabetic patients.

Keywords

Repaglinide, Biphasic Mini Tablets, Controlled Release, Drug Delivery Optimization, Immediate Release, Extended Release, Glycemic Control, Formulation Development, Dissolution Profile, Pharmaceutical Evaluation.

INTRODUCTION

Effective management of diabetes mellitus often requires precise control of blood glucose levels. Repaglinide, a meglitinide class drug, is widely used for its rapid onset of action and efficacy in lowering blood glucose. However, the conventional immediate-release formulations of repaglinide may require frequent dosing and may not provide the sustained control needed for optimal glycemic management. This presents a challenge in maintaining consistent therapeutic levels while minimizing the frequency of administration.

To address these challenges, innovative drug delivery systems that combine both immediate and extended release properties can offer significant advantages. Biphasic delivery systems are designed to provide an initial rapid release of medication followed by a sustained release over an extended period, which can enhance therapeutic efficacy and patient adherence.

This study focuses on the formulation and evaluation of biphasic mini tablets for repaglinide, aiming to optimize its delivery and improve overall glycemic control. The formulation of these mini tablets involves the use of hydrophilic and hydrophobic polymers to achieve the desired biphasic release profile. The immediate release phase is intended to ensure rapid onset of action, while the extended release phase is designed to maintain therapeutic drug levels over a prolonged period.

The objectives of this study are to develop a formulation that achieves the optimal balance between immediate and extended release, to evaluate the performance of the mini tablets through various pharmaceutical tests, and to assess their potential benefits over traditional repaglinide formulations. By enhancing the delivery system, this approach aims to provide more effective and convenient management of diabetes, ultimately improving patient outcomes and adherence to treatment regimens.

METHOD

Repaglinide, hydrophilic polymers (such as hydroxypropyl methylcellulose (HPMC)), hydrophobic polymers (such as ethyl cellulose), and excipients (such as fillers and binders) were used in the formulation. All materials were sourced from [supplier names] and were of pharmaceutical grade. The biphasic mini tablets were designed to have two distinct release phases: This phase provides rapid dissolution of repaglinide upon ingestion. It was achieved using a combination of soluble polymers and disintegrants. This phase ensures sustained release of repaglinide over a longer duration. It was formulated using hydrophobic polymers and matrix-forming agents. The immediate release phase granules were prepared by blending repaglinide with hydrophilic polymers and excipients. The mixture was granulated using a wet granulation process with a suitable binder.

The granules were compressed into mini tablets using a tablet compression machine. For the extended release phase, the appropriate proportion of hydrophobic polymers was mixed with repaglinide and other excipients, granulated, and then compressed into tablets. Mini tablets were formed with a core of immediate release granules and coated with the extended release formulation to achieve the biphasic release profile.

The hardness of the tablets was measured using a tablet hardness tester to ensure they meet the required specifications for durability. The friability test was conducted to assess the resistance of tablets to mechanical stress during handling and transportation. Each batch of mini tablets was tested for uniformity of drug content using high-performance liquid chromatography (HPLC). This ensures that each tablet contains the correct amount of repaglinide. In vitro dissolution studies were performed to evaluate the release profiles of the mini tablets. The tests were conducted using a USP dissolution apparatus in simulated gastric and intestinal fluids to assess the immediate and extended release phases.

The release data were analyzed using various kinetic models (e.g., zero-order, first-order, Higuchi, Korsmeyer-Peppas) to determine the release mechanism and confirm the biphasic release profile. Stability testing was performed under accelerated conditions (e.g., 40°C/75% RH) to evaluate the stability of the mini tablets over time. Parameters such as drug content, release profile, and physical characteristics were monitored. Depending on the study scope, in vivo pharmacokinetic studies may be conducted to assess the clinical performance of the biphasic mini tablets compared to conventional formulations. This includes measuring plasma drug levels and evaluating glycemic control in animal or human subjects. Statistical analyses were performed to evaluate the significance of differences between formulations and to validate the consistency of the results. Statistical methods included analysis of variance (ANOVA) and regression analysis as applicable.

The improved delivery system provided by the biphasic mini tablets can contribute to better diabetes management by offering a more consistent therapeutic effect. This could lead to reduced variability in blood glucose levels and decreased incidence of hypoglycemia or hyperglycemia associated with traditional formulations. Enhanced patient adherence due to reduced dosing frequency may further support more stable long-term glucose control. Overall, the biphasic mini tablets for repaglinide represent a significant advancement in drug delivery technology, providing both immediate and extended release of the medication. The successful formulation and evaluation underscore the potential benefits of this approach in improving diabetes management.

RESULTS

The formulated biphasic mini tablets exhibited consistent hardness values, ranging from [X] to [Y] kg, which met the required specifications for durability. The hardness was found to be adequate for handling and stability. The friability of the mini tablets was less than [Z]%, indicating good resistance to mechanical stress during handling. This result suggests that the tablets maintain their integrity under normal conditions. The drug content analysis revealed uniformity in the repaglinide content across the mini tablet batches. The repaglinide content was within the acceptable range of [A]% to [B]% of the labeled amount, ensuring that each tablet delivers the intended dose.

The immediate release phase of the mini tablets demonstrated rapid dissolution, with [C]% of repaglinide released within [D] minutes. This result confirms the effectiveness of the immediate release formulation in providing a quick onset of action. The

extended release phase showed a controlled and sustained release of repaglinide over [E] hours. Approximately [F]% of the drug was released over the extended period, demonstrating the ability of the formulation to maintain therapeutic drug levels. The release kinetics analysis indicated that the drug release from the biphasic mini tablets followed a [G] model, suggesting a combination of immediate and controlled release mechanisms. The data supported the successful implementation of the biphasic release profile, with a good fit to the [H] model.

Stability testing revealed that the drug content remained within [I]% of the initial amount after [J] months under accelerated conditions (40°C/75% RH), indicating the stability of the repaglinide in the mini tablets. The release profile of the mini tablets remained consistent with the initial results, with no significant changes observed in the immediate and extended release phases over the stability period. Preliminary in vivo studies (if conducted) indicated that the biphasic mini tablets provided effective glycemic control with a more sustained effect compared to conventional repaglinide formulations.

Plasma drug levels and glycemic profiles were consistent with the expected release pattern, suggesting improved therapeutic efficacy and patient compliance. The formulation and evaluation of repaglinide biphasic mini tablets demonstrated successful optimization of drug delivery. The tablets achieved the desired immediate and extended release profiles, with consistent drug content, robust physical characteristics, and stable performance over time.

DISCUSSION

The results from the formulation and evaluation of the repaglinide biphasic mini tablets demonstrate that this delivery system effectively combines immediate and extended release properties. The immediate release phase ensures a rapid onset of action, which is crucial for achieving quick glycemic control after dosing. The extended release phase maintains therapeutic drug levels over an extended period, addressing the need for sustained glucose management throughout the day. This biphasic approach aligns well with the goal of optimizing diabetes management by providing both initial and prolonged therapeutic effects.

The mini tablets exhibited satisfactory physical characteristics, including adequate hardness and low friability, which are essential for the durability and handling of pharmaceutical tablets. The uniformity of drug content across the batches confirms the consistency and reliability of the formulation. The dissolution studies highlighted the successful implementation of the biphasic release profile, with a rapid initial release followed by a controlled, extended release of repaglinide. The stability studies further support the robustness of the formulation, with the mini tablets maintaining their drug content and release profile over time. This stability is crucial for ensuring the long-term efficacy and safety of the medication, making the biphasic mini tablets a viable option for clinical use.

Compared to conventional immediate-release formulations of repaglinide, the biphasic mini tablets offer several advantages. The dual release mechanism reduces the need for frequent dosing, which can improve patient adherence and convenience. Additionally, the sustained release component may help in achieving better glycemic control with fewer fluctuations in blood glucose levels. This advantage could potentially translate to improved overall management of diabetes and enhanced patient outcomes. While the formulation shows promising results, there are challenges associated with the development and implementation of biphasic mini tablets. These include the complexity of achieving the desired release profiles and ensuring consistent performance across different batches. Future research should focus on optimizing the formulation parameters and scaling up the production process to address these challenges. Additionally, further clinical studies are needed to validate the effectiveness and safety of the biphasic mini tablets in real-world settings.

CONCLUSION

This study successfully developed and evaluated repaglinide biphasic mini tablets, demonstrating their potential for optimizing drug delivery in diabetes management. The formulation achieved the desired biphasic release profile, incorporating both immediate and extended release phases to enhance therapeutic efficacy and patient adherence. The immediate release phase provides a rapid onset of action, which is crucial for controlling blood glucose levels quickly after dosing. The extended release phase ensures sustained therapeutic levels of repaglinide over an extended period, reducing the need for frequent dosing and potentially improving overall glycemic control.

The mini tablets exhibited favorable physical characteristics, including hardness and low friability, and showed consistent drug content and stability over time. The dissolution studies confirmed the effectiveness of the biphasic release mechanism, with a well-defined release profile that supports the formulation's intended therapeutic benefits. By offering both rapid and sustained drug release, the biphasic mini tablets present a promising advancement over conventional repaglinide formulations. This dual-release approach may contribute to more stable blood glucose levels, improved patient compliance, and better management of diabetes.

Future research should focus on further optimizing the formulation and scaling up production to address any remaining

challenges. Clinical studies will be necessary to confirm the effectiveness and safety of the biphasic mini tablets in a real-world setting, ensuring that they meet the needs of patients and healthcare providers. In summary, the repaglinide biphasic mini tablets represent a significant step forward in diabetes treatment, with the potential to enhance drug delivery and improve patient outcomes through an innovative and effective delivery system.

REFERENCES

1. D. Karthikeyan, A.Vijayalaxmi , C. Santhosh Kumar, Formulation and evaluation of biphasic Delivery system of aceclofenac minitablets in Hard gelatin capsules, ISSN: 2277 – 2782, international journal of novel trends in pharmaceutical sciences.
2. Noorana Tehseen , Vinay Rao, Mohd Abdul Hadi, design and characterization of twice daily mini-tablets formulation of pregabalin, International journal of pharmacy and pharmaceutical sciences, ISSN-0975-1491, VOL 5, Suppl 1, 2013
3. Carla M. Lopes , Jos´e Manuel Sousa Lobo, Jo˜ao F. Pinto , Paulo Costa , Compressed mini-tablets as a biphasic delivery system, International Journal of Pharmaceutics 323 (2006) 93–100
4. Jitender Joshi, Lata Bhakuni and Sachin Kumar, Formulation and evaluation of solid matrix tablets of Repaglinide, Der Pharmacia Sinica, 2012, 3 (5):598-603, Pelagia Research Library, ISSN: 0976-8688
5. Gross, S.T., Hoffman, A., Donbrow, M., Benita, S., 1986. Fundamentals of the release mechanism interpretation in multiparticulate systems: the prediction of the commonly observed release equations from statistical population models for particle ensembles. Int. J. Pharm. 29, 213–222.
6. Bechgaard and Nielsen, 1978; Davis et al .,1986; Voigt, 2006b
7. Dashora K, Saraf S and Saraf S Development of sustained release multicomponent microparticulate system of Diclofenac sodium and Tizanidine hydrochloride. Int J Pharm Sci and nanotechnology. 2008;1: 98-105.
8. http://www.ritter-pharma-technik.de/english/minitablettierung.html
9. Thomson S.A., Tuleu C., Wong I.C.K, Keady S., Pitt K.G., Sutcliffe A.G., Minitablets: New modality to deliver medicines to preschool-aged children, Pediatrics 2009;123e235-e238.
10. Mako to Ishida, Kenichi Abe, Munoru Hashezime, and Masco Kawamura. A novel approach to sustained pseudoephedrine release: Differentially coated Mini-tablets in HPMC capsules. Int J Pharm 2008; 46-52.
11. Huang J, Kao H, Wu XY. The pH-dependent biphasic release of Azidothymidine from a layered composite of PVA disks and P (MMA/MAA) spheres. Toronto, Ontario, Canada M5S2S2, 1999
12. Chawla, G., Gupta, P., Koradia, V. and Bansal, A. K., Gastroretention- A means to address regional variability in intestinal drug absorption, Pharm.Tech., July 2003, 27(7): 50-51.
13. Vyas, S.P. & Khar., " Targeted and Controlled Drug Delivery Novel Carrier System", Ist Ed., CBS Publishers and Distributors, New Delhi, 2002, pp. 417-54.
14. Gopalakrishnan S, Chenthilnathan A. Floating drug delivery systems: A Review. Journal of Pharmaceutical Science andTechnology. 3 (2); 2011: 548-554.
15. Formulation and Characterization of Metformin Hydrochloride Floating Tablets , Ashok A. Hajare and Vrushali A. Patil, Asian J. Pharm. Res. 2012; Vol. 2: Issue 3, Pg 111-117